Health Care Equipment

Electrocore

Electrocore released FY2026 Q1 earnings on May 6 After-Market EST, actual revenue USD 9.584 M (forecast USD 9.443 M), actual EPS USD -0.59 (forecast USD -0.6125)

Electrocore to Release FY2026 Q1 Earnings on May 6 After-Market EST, Forecast Revenue USD 9.011 M, EPS USD -0.612

Electrocore released FY2025 Q4 earnings on March 19 After-Market EST, actual revenue USD 9.243 M (forecast USD 9.126 M), actual EPS USD -0.3453 (forecast USD -0.3925)

Electrocore released FY2025 earnings on March 19 After-Market EST, actual revenue USD 32.03 M (forecast USD 31.95 M), actual EPS USD -1.6463 (forecast USD -1.724)

Electrocore to Release FY2025 Q4 Earnings on March 19 After-Market EST, Forecast Revenue USD 9.093 M, EPS USD -0.404

Electrocore released FY2025 9 Months Earnings on November 5 After-Market EST, with actual revenue of USD 22.79 M and EPS of USD -1.3097

Electrocore released FY2025 Q3 earnings on November 5 After-Market (EST), actual revenue USD 8.689 M (forecast USD 7.876 M), actual EPS USD -0.4031 (forecast USD -0.4)

Electrocore to Release FY2025 Q3 Earnings on November 5 After-Market EST, Forecast Revenue USD 7.876 M, EPS USD -0.4

Electrocore released FY2025 Semi-Annual earnings on August 6 After-Market EST, actual revenue USD 14.1 M, actual EPS USD -0.9065

Electrocore released FY2025 Q2 earnings on August 6 After-Market EST, actual revenue USD 7.381 M (forecast USD 7.237 M), actual EPS USD -0.4414 (forecast USD -0.325)

Electrocore to Release FY2025 Q2 Earnings on August 6 After-Market EST, Forecast Revenue USD 7.237 M, EPS USD -0.325

Electrocore released FY2025 Q1 earnings on May 7 After-Market EST, actual revenue USD 6.719 M (forecast USD 6.929 M), actual EPS USD -0.465 (forecast USD -0.4466)

electroCore Acquires Quell® Platform to Enhance Bioelectronic Technology Portfolio

electroCore Inc. Product Now Compatible with Apple Health

Electrocore to release FY2025 Q1 earnings on May 7 After-Market EST, forecast revenue USD 6.929 M, EPS USD -0.4466

electroCore Releases New Data at 2025 International Brain Injury Association World Congress

electroCore, Inc. stock price drops 59% over the past month, despite expected 28% annual growth in the next three years

Electrocore released FY2024 Q4 earnings on March 12 After-Market EST, actual revenue USD 7.046 M (forecast USD 7.055 M), actual EPS USD -0.3952 (forecast USD -0.3)

Electrocore released FY2024 annual earnings on March 12 After-Market (EST), actual revenue 25.18 M USD (forecast 25.19 M USD), actual EPS -1.59 USD (forecast -1.502 USD)

Electrocore to Release FY2024 Q4 Earnings on March 12 After-Market EST, Forecast Revenue 7.055 M USD, EPS -0.3 USD

Akanda

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Co-Diagnostics

Agape ATP

NewGenIvf

Netcapital

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Tradr 2X Long QBTS Daily ETF

Liminatus Pharma

Defiance Daily Target 2X Long RGTI ETF

ECOR

electroCore (NASDAQ:ECOR) Interim President and CFO Joshua Lev announced a 30% growth outlook, focusing on expanding its vagus nerve stimulation platform across federal healthcare and consumer markets. The company reported a revenue growth rate of over 50% annually and improved gross profit margins. Lev highlighted the VA as a key customer, with significant opportunities in federal health systems. The recent acquisition of NeuroMetrix has boosted revenue from fibromyalgia products, and partnerships with influencers are enhancing consumer wellness sales.

Market Beat

NeuroMetrix

electroCore Touts 30% Growth Outlook, VA Opportunity at LD Micro Conference

HC Wainwright analysts forecast electroCore, Inc. (NASDAQ:ECOR) will report Q1 2027 earnings of ($0.37) per share, maintaining a "Buy" rating with an $18.00 price target. The consensus for the full year is ($1.46) per share. The company recently reported Q1 results of ($0.59) EPS, meeting expectations, with revenues of $9.58 million. Institutional investors hold 26.74% of shares, while insiders own 13.80%. electroCore specializes in non-invasive vagus nerve stimulation therapies for neurological and inflammatory conditions.

Q1 Earnings Forecast for electroCore Issued By HC Wainwright

electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026 | ECOR Stock News

StockTitan

electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026 | ECOR Stock News

Electrocore's Q1 earnings call highlighted record revenue of $9.6 million, a 43% year-over-year increase, and a narrowing adjusted EBITDA loss of $2.3 million. The company reaffirmed its full-year guidance for approximately 30% revenue growth, driven by strong performance in the VA channel and consumer wellness segments. Despite a GAAP net loss widening to $5.3 million due to one-time transition costs, management remains optimistic about growth opportunities. However, cash burn and elevated SG&A expenses are concerns as the company continues to invest in expansion.

Tip Ranks

Electrocore Earnings Call Highlights Growth Amid Losses

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Electrocore(ECOR.US)

electroCore Touts 30% Growth Outlook, VA Opportunity at LD Micro Conference

Q1 Earnings Forecast for electroCore Issued By HC Wainwright

electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026 | ECOR Stock News

Electrocore Earnings Call Highlights Growth Amid Losses

electroCore (ECOR) Q1 2026 Earnings Transcript

Electrocore | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 9.584 M

Electrocore | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 9.584 M